Résumé
The advent of BRAF and MEK inhibitors changed the landscape of the management of BRAF mutated melanoma patients. In this article, we report the case of a 51-year-old man with BRAF mutated locally advanced cutaneous melanoma of the head who demonstrated a limited response to initial anti-BRAF monotherapy followed by extensive surgery. Anti-PD1 therapy failed to reverse the disease progression. However, subsequent double inhibition of the BRAF and MEK pathways induced a fast and remarkable tumour response.
langue originale | Anglais |
---|---|
Pages (de - à) | 1052-1054 |
Nombre de pages | 3 |
journal | Anti-Cancer Drugs |
Volume | 30 |
Numéro de publication | 10 |
Les DOIs | |
état | Publié - 1 nov. 2019 |
Modification externe | Oui |